Search

Your search keyword '"Ventre, Marta Bruno"' showing total 10 results
Start Over Author "Ventre, Marta Bruno"
10 results on '"Ventre, Marta Bruno"'

3. Risk-Tailored CNS Prophylaxis In 194 Patients With Diffuse Large B-CELL Lymphoma (DLBCL) Treated In The Rituximab ERA: Risk Definition By Clinical Variables and Ontogenic Stratification

Author

Ventre, Marta Bruno, primary, Foppoli, Marco, additional, Citterio, Giovanni, additional, Donadoni, Giovanni, additional, Ponzoni, Maurilio, additional, Govi, Silvia, additional, Scarfò, Lydia, additional, Sassone, Marianna, additional, Caligaris -Cappio, Federico, additional, and Ferreri, Andres J.M., additional

Published
2013
Full Text
View/download PDF

4. Interim Analysis Of An Ongoing PHASE II Trial Assessing Safety and Efficacy Of Lenalidomide Maintenance In Patients With Chemosensitive Relapse Of Diffuse Large B-CELL Lymphoma (DLBCL)

Author

Govi, Silvia, primary, Ventre, Marta Bruno, additional, Zaja, Francesco, additional, Di Rocco, Alice, additional, Spina, Michele, additional, Vallisa, Daniele, additional, Scarfo', Lydia, additional, Chiozzotto, Marianna, additional, Cuccurullo, Rosanna, additional, Fama, Angelo, additional, and Ferreri, Andrés J.M., additional

Published
2013
Full Text
View/download PDF

5. Non Pegilated Liposomal Doxorubicin (TLC-D99; Myocet ™) Can Be Safely and Effectively Used As Part of the R-COMP Regimen in Patients with Diffuse Large B-Cell Lymphoma Who Show Contraindications to Anthracyclines Due to Concomitant Moderate/Severe Heart Disease. Results of the HEART01 Phase II trial by the Fondazione Italiana Linfomi (NCT01009970)

Author

Spina, Michele, primary, Luminari, Stefano, additional, Ferreri, Andrés J.M., additional, Zaja, Francesco, additional, Balzarotti, Monica, additional, Salvi, Flavia, additional, Micheletti, Moira, additional, Musuraca, Gerardo, additional, Viel, Elda, additional, Volpetti, Stefano, additional, Pesce, Emanuela Anna, additional, Ventre, Marta Bruno, additional, and Federico, Massimo, additional

Published
2012
Full Text
View/download PDF

6. Final Results of a Multicenter Phase II Trial with Translational Elements to Investigate the Possible Infective Causes of Ocular Adnexal Marginal Zone B-Cell Lymphoma (OAMZL) with Particular Reference to Chlamydia Species and the Efficacy of Doxycycline As First-Line Lymphoma Treatment (the IELSG#27 TRIAL)

Author

Govi, Silvia, primary, Dolcetti, Riccardo, additional, Ponzoni, Maurilio, additional, Pasini, Elisa, additional, Mappa, Silvia, additional, Ventre, Marta Bruno, additional, Doglioni, Claudio, additional, Bertoni, Francesco, additional, Zaja, Francesco, additional, Montalban, Carlos, additional, Stelitano, Caterina, additional, Cabrera, Maria Elena, additional, Cavalli, Franco, additional, Zucca, Emanuele, additional, and Ferreri, Andrés J.M., additional

Published
2011
Full Text
View/download PDF

7. Safety and Activity of Intensive Short-Term Chemoimmunotherapy in HIV-Positive (HIV+) Patients (pts) with Burkitt Lymphoma (BL)

Author

Ventre, Marta Bruno, primary, Donadoni, Giovanni, additional, Re, Alessandro, additional, Spina, Michele, additional, Cattaneo, Chiara, additional, Fumagalli, Luca, additional, Mappa, Silvia, additional, Govi, Silvia, additional, Rossi, Giuseppe, additional, Tirelli, Umberto, additional, and Ferreri, Andrés JM, additional

Published
2011
Full Text
View/download PDF

8. WT1 Transcripts Is a Powerful Leukemia Marker to Predict Early Relapse After Allogeneic Haematopoietic Stem Cell Transplantation.

Author

Messina, Carlo, primary, Tresoldi, Cristina, additional, Stanghellini, Maria Teresa Lupo, additional, Crotta, Alessandro, additional, Girlanda, Stefania, additional, Coppola, Milena, additional, Piemontese, Simona, additional, Greco, Raffaella, additional, Malato, Simona, additional, Forno, Barbara, additional, Assanelli, Andrea, additional, Clerici, Daniela, additional, Mastaglio, Sara, additional, Giglio, Fabio, additional, Ventre, Marta Bruno, additional, Lunghi, Francesca, additional, Guggiari, Elena, additional, Carrabba, Matteo Giovanni, additional, Marcatti, Magda, additional, Corti, Consuelo, additional, Bonini, Chiara, additional, Fleischhauer, Katharina, additional, Peccatori, Jacopo, additional, Bordignon, Claudio, additional, Ciceri, Fabio, additional, and Bernardi, Massimo, additional

Published
2009
Full Text
View/download PDF

9. Selective intra-graft apoptosis and down-regulation of lymphocyte bcl-2, iNOs and CD95L expression in kidney-pancreas transplanted patients after anti-Thymoglobulin induction

Author

Fiorina, Paolo, primary, Torriani, Gabriele, additional, Gremizzi, Chiara, additional, Davalli, Alberto M., additional, Orsenigo, Elena, additional, Ventre, Marta Bruno, additional, Dell'Antonio, Giacomo, additional, Carlo, Valerio, additional, Rossini, Silvano, additional, and Secchi, Antonio, additional

Published
2004
Full Text
View/download PDF

10. Clinical Features,Management, and Prognosis of an International Series of 161 Patients With Limited-Stage Diffuse Large B-Cell Lymphoma of the Bone (the IELSG-14 Study)

Author

Ventre, Marta Bruno, Ferreri, Andr´Es J. M., Gospodarowicz, Mary, Govi, Silvia, Messina, Carlo, Porter, David, Radford, John, Heo, Dae Seog, Park, Yeon, Martinelli, Giovanni, Taylor, Emma, Lucraft, Helen, Hong, Angela, ScarfÒ, Lydia, Zucca, Emanuele, and Christie, David

Abstract

Introduction. The clinical features, management, and prognosis of stage I-II diffuse large B-cell lymphoma of the bone (PBDLBCL) included in an international database of 499 lymphoma patients with skeletal involvement were reviewed. Methods. HIV-negative patients (n 5 161) with diffuse large B-celllymphoma of the bone (PB-DLBCL) after complete staging workup were considered. The primary objective of this study was to identify the most effective treatment modality; the secondary objectives were to define the contribution of irradiation fields and doses and the pattern of relapse. Results. Median age was 55 years (range, 18-99 years), with a male/female ratio of 1:2; 141 (87%) patients had stage I, 14 (9%) had B symptoms, 37 (23%) had bulky lesion, 54 (33%) showed elevated lactate dehydrogenase serum levels, and 25 (15%) had fracture. Thirteen (8%) patients received chemotherapy alone, 23 (14%) received radiotherapy alone, and 125 (78%) received both treatments. The response to the first-line treatment was complete in 131 of 152 assessed patients (complete response rate, 86%; 95% confidence interval [CI], 81%-91%) and partial in 7, with an overall response rate of 91% (95% CI, 87%-95%). At a median follow-up of 54 months (range,3-218),107(67%)patients remained relapse-free, with a 5-year progression-free survival of 68% (SE: 4). Four (2.5%) patients had meningeal relapse; 119 patients were alive (113 disease-free), with a 5-year overall survival of 75% (SE: 4). Patients managed with primary chemotherapy, whether followed by radiotherapy or not, had a significantly better outcome than patients treated with primary radiotherapy, whether followed by chemotherapy or not. The addition of consolidative radiotherapy after primary chemotherapy was not associated with improved outcome; doses.36 Gy and the irradiation of the whole affected bone were not associated with better outcome. Conclusion. Patients with PB-DLBCL exhibit a favorable prognosis when treated with primary anthracycline-based chemotherapy whether followed by radiotherapy or not. In patients treated with chemoradiotherapy, the use of larger radiation fields and doses is not associated with better outcome. Central nervous system dissemination is a rare event in PB-DLBCL patients. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results